Biotechnology company United Therapeutics (NASDAQ: UTHR) will be announcing earnings results this Wednesday before market hours. Here’s what investors should know.
United Therapeutics beat analysts’ revenue expectations last quarter, reporting revenues of $783.3 million, down 1.9% year on year. It was a strong quarter for the company, with a beat of analysts’ EPS estimates.
Is United Therapeutics a buy or sell going into earnings? Read our full analysis here, it’s free for active Edge members.
This quarter, the market is expecting United Therapeutics’s revenue to decline 2.1% year on year, a reversal from the 6.8% increase it recorded in the same quarter last year.
Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business will stay the course heading into earnings. United Therapeutics has missed Wall Street’s revenue estimates multiple times over the last two years.
Looking at United Therapeutics’s peers in the therapeutics segment, some have already reported their Q3 results, giving us a hint as to what we can expect. Biogen delivered year-on-year revenue growth of 10.6%, beating analysts’ expectations by 6.4%, and Gilead Sciences reported revenues up 6.8%, topping estimates by 6.3%. Biogen traded down 1.2% following the results while Gilead Sciences was up 4.1%.
Read our full analysis of Biogen’s results here and Gilead Sciences’s results here.
There has been positive sentiment among investors in the therapeutics segment, with share prices up 2.4% on average over the last month. United Therapeutics is up 11.2% during the same time and is heading into earnings with an average analyst price target of $670.93 (compared to the current share price of $596.45).
WHILE YOU’RE HERE: The Next Palantir? One satellite company captures images of every point on Earth. Every single day. The Pentagon wants it. Hedge funds are using it to beat earnings. You’ve probably never heard of it.
This is what the early days of Palantir looked like before it became a giant. Same playbook. Different technology. If you missed Palantir, you need to see this. Claim The Stock Ticker for Free HERE.
